Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RCS-01 for Skin Aging
NCT02391935Phase 1Completed
- Sponsor
- RepliCel Life Sciences Inc.
- Start
- Oct 2015
- Primary completion
- Jul 2017
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Skin aging comparing RCS-01 Subgroup with Placebo Subgroup (2 arms). Primary endpoint: Incidence of local adverse events at 52 weeks. Started Oct 2015; status: completed.
02
Drugs
RCS-01
03
Conditions
Skin aging
Beyond the preview
Go deeper on NCT02391935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02391935.